Company / Cost of Revenue
Amylyx Pharmaceuticals, Inc. Cost of Revenue History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
-
FY2025
5-year range
$0 / $25.4M
FY2022-FY2025
Trend
-100.0%
vs FY2024
Sector context
#83 of 85
Health Care
What the data says
Improved from $25M to $0 over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 85
▼
Key checks
Key Insights
- In FY2025, cost of revenue decreased 100.0% year-over-year.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0 | -100.0% |
| FY2024 | $6.0M | -76.6% |
| FY2023 | $25.4M | +750.0% |
| FY2022 | $3.0M | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026